Recursion Pharmaceuticals (NASDAQ:RXRX), an AI-enabled clinical-stage drug discovery company, closed at $2.83, up 3.86%. The stock rose after the company said it reached FDA alignment on the REC-4881 Phase 3 design, and investors are watching for further regulatory detail. Trading volume reached 39.4M shares, coming in about 65% above its three-month average of 23.8M shares. Recursion Pharmaceuticals IPO'd in 2021 and has fallen 91% since going public.
S&P 500 (SNPINDEX:^GSPC) closed at 7,323, down 0.24%, while Nasdaq Composite (NASDAQINDEX:^IXIC) finished at 24,430, up 0.42%. In biotechnology: AI-enabled drug discovery and clinical-stage therapeutics, Schrödinger (NASDAQ:SDGR) closed at $27.20, up 6.00%, and Relay Therapeutics (NASDAQ:RLAY) closed at $16.51, up 0.24%.
Recursion shares are up 4% today after it aligned with the FDA on a Phase III trial design for 200 adults with familial adenomatous polyposis. The disease currently has no approved therapies, making Recursion's REC-4881 one of the first AI-enabled treatments to advance toward a Phase III trial.
Recursion believes there are over 50,000 patients with familial adenomatous polyposis in the U.S. and E.U., representing a $15 billion market opportunity for the $1.7 billion company. The FDA accepted 10 mm or larger polyp excision as part of its primary endpoint of event-free survival, which could be a win for RXRX stock, as it shouldn't have to run a longer, costlier trial waiting for adverse events to develop further.
While today's development is great progress for the stock, the results of the Phase III trial itself remain paramount, as success with REC-4881 would serve as a proof of concept not just for Recursion but for its AI platform. The Phase III trial won't begin until the second half of 2027, however, so interested investors need to be uber-patient and risk-tolerant before considering this stock.
Before you buy stock in Recursion Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Recursion Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $321,850!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $955,232!*
Now, it’s worth noting Stock Advisor’s total average return is 793% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 18, 2026.
Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Schrödinger. The Motley Fool has a disclosure policy.